UK MHRA Probes Peptide Clinics Over Unlawful BPC-157 and MOTS-C Health Claims
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.